Your session is about to expire
← Back to Search
PDT Triple Therapy for Age-Related Macular Degeneration
Study Summary
This trial found that OCTA-directed PDT triple therapy is more effective than standard of care anti-VEGF monotherapy for treating patients with exudative age-related macular degeneration.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are willing and able to comply with all study procedures for the duration of the study.You have a condition called optic neuropathy.You had a heart attack or stroke in the past 6 weeks.You are a female of childbearing potential who is willing to use medically acceptable methods of birth control.You are allergic to fluorescein, indocyanine, or medications used to dilate your eyes or treat VEGF-related conditions.You have previously been treated for age-related macular degeneration (ARMD).You have previously received treatments like laser therapy, medication injections, or a type of photodynamic therapy called Visudyne.
- Group 1: Arm C: Lucentis, PDT Laser and Triescense
- Group 2: Arm A: Lucentis
- Group 3: Arm B: Lucentis & PDT Laser
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What medical concerns can Ranibizumab be utilized to treat?
"Ranibizumab is a therapeutic agent used to address ulcerative colitis, hand conditions and brain pathologies."
Are enrollees still being accepted for this scientific experiment?
"Unfortunately, this research trial is not currently open to recruitment. It was initially made available on November 1st 2022 and the latest revision occurred on August 23rd 2022. In terms of other opportunities, there are 159 studies that are actively searching for individuals with macular degeneration and 74 trials recruiting patients who have been prescribed Ranibizumab."
What detrimental effects have been associated with Ranibizumab?
"According to our team at Power, Ranibizumab is considered safe and has been granted a score of 3. This medication is currently in Phase 4 clinical trials which suggest it may be approved soon."
Is this research study enrolling participants who are more than half a century of age?
"This medical experiment allows individuals who are aged between 50 and 90 to participate."
What is the aggregate sum of participants in this clinical experiment?
"This study is no longer recruiting participants, having been last updated on August 23rd 2022. However, if you are interested in macular degeneration trials there are presently 159 studies actively seeking volunteers and 74 for Ranibizumab."
Is it feasible for me to partake in this research project?
"This clinical trial is admitting 150 patients with age between 50 and 90 who are suffering from macular degeneration. To qualify, individuals must meet the requirements of having exudative ARMD with evidence of choroidal neovascularization (type 1, 2 or 3) on spectral domain OCT, fluorescein angiography, indocyanine green angiogram and optical coherent tomography angiography; visual acuity ranging from 20/25 to 20/400 at screening and baseline visits using an autorefractor or Early Treatment Diabetic Retinopathy Study; intraocular pressure not exceeding 25mmHG;"
Could you provide information on prior investigations of Ranibizumab?
"Presently, 74 medical trials are evaluating the efficacy of ranibizumab. Of them, 22 are in phase 3 and they span 897 different sites across Columbia Missouri."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger